Hidden trauma: new study reveals psychological toll of cervical cancer radiation
NCT ID NCT07204535
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 80 cervical cancer patients who receive brachytherapy (internal radiation) to see if they develop post-traumatic stress disorder (PTSD). Participants fill out questionnaires about PTSD, anxiety, depression, quality of life, and sexual health over 5 years. The goal is to understand how common these psychological effects are and who might need extra support.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this study could help doctors identify patients at risk for post-traumatic stress after brachytherapy and develop better psychological support.
- What could go wrong
- This is an observational study, not a treatment trial. It only measures symptoms and does not test any new therapy, so direct patient benefit is limited.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 80 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Nov 2025
- Expected to finish
-
Nov 2031
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patient with cervical cancer with an indication for High-dose rate (HDR) or pulse-dose rate (PDR) uterovaginal brachytherapy
- Ages
-
18 years and older
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Confirmed diagnosis of cervical cancer with an indication for High-dose rate (HDR) or pulse-dose rate (PDR) uterovaginal brachytherapy; * Squamous cell carcinoma or other histological types; * WHO ≤ 2; * Ability to complete validated questionnaires in French; * Informed consent to participate in the study; * Patients over 18 years old Exclusion Criteria: * Inability to understand or respond to questionnaires due to a cognitive disorder, intellectual disability, language barrier, or psychiatric disorder that impairs judgment; * Patient under juridic protection; * Pregnant or breastfeeding woman
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cervical cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
2 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Groupement Hospitalier Sud - Hopital Lyon Sud
RECRUITINGPierre-Bénite, 69495, France
-
ICANS
RECRUITINGStrasbourg, 67033, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can pulsed radiation extend life in metastatic cervical cancer?
- Robotic surgery vs standard approaches: does the platform change cancer outcomes?
- New antibody aims to preserve immune checkpoint while fighting cancer
- Smart speculum could bring cervical cancer screening to remote areas
- Your gut bacteria may hold the key to whether immunotherapy works
- Amazon plant put to the test against Cancer's relentless tiredness